Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Top Drugs
Top drugs added weekly
| Term | Definition |
|---|---|
| lisinopril (brand) | zestril |
| lisinopril (class) | angiotensin converting enzyme (ACE) inhibitor |
| lisinopril (category) | antihypertensive |
| lisinopril (BMA) | inhibits the conversion of angiotensin I to angiotensin II, causing vasodilation and reduction in the release of aldosterone |
| amlodipine (brand) | norvasc (tab), norliqva (soln), katerzia (susp) |
| amlodipine (class) | calcium channel blocker |
| amlodipine (category) | antihypertensive |
| amlodipine (BMA) | inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in decreased peripheral vascular resistance and reduced blood pressure |
| losartan (brand) | cozaar |
| losartan (class) | angiotensin II receptor blocker (ARB) |
| losartan (category) | antihypertensive |
| losartan (BMA) | selectively blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and reducing the secretion of aldosterone |
| hydrochlorothiazide (brand) | microzide, hydrodiuril, aquazide h |
| hydrochlorothiazide (class) | thiazide diuretic |
| hydrochlorothiazide (catergory) | antihypertensive |
| hydrochlorothiazide (BMA) | inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water, as well as potassium and hydrogen ions |
| furosemide (brand) | lasix |
| furosemide (class) | loop diuretic |
| furosemide (catergory) | antihypertensive |
| furosemide (BMA) | inhibits the reabsorption of sodium and chloride in the ascending loop of Henle and distal renal tubule |
| atenolol (brand) | tenormin |
| atenolol (class) | beta blocker |
| atenolol (category) | antihypertensive |
| atenolol (BMA) | selectively blocks beta 1 adrenergic receptors in the heart decreasing heart rate and contractility |
| bisoprolol (brand) | cardicor |
| bisoprolol (class) | beta blocker |
| bisoprolol (category) | antihypertensive |
| bisoprolol (BMA) | selectively blocks beta 1 adrenergic receptors in the heart decreasing heart rate and contractility |
| carvedilol (brand) | coreg |
| carvedilol (class) | beta blocker with alpha blocking activity |
| carvedilol (category) | antihypertensive |
| carvedilol (BMA) | nonselectively blocks beta adrenergic receptors and alpha 1 adrenergic receptors, leading to decreased heart rate, contractility, and increased vasodilation |
| propranolol (brand) | inderal |
| propranolol (class) | beta blocker |
| propranolol (cateogory) | antihypertensive |
| propranolol (BMA) | nonselectively blocks beta adrenergic receptors, reducing heart rate and contractility |
| nifedipine (brand) | procardia |
| nifedipine (class) | calcium channel blocker |
| nifedipine (category) | antihypertensive |
| nifedipine (BMA) | inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in decreased peripheral vascular resistance and reduced blood pressure |
| hydralazine (brand) | apresoline |
| hydralazine (class) | vasodilator |
| hydralazine (category) | antihypertensive |
| hydralazine (BMA) | directly relaxes arteriolar smooth muscle, reducing peripheral vascular resistance |
| valsartan (brand) | diovan |
| valsartan (class) | angiotensin II receptor blocker (ARB) |
| valsartan (category) | antihypertensive |
| valsartan (BMA) | selectively blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and reducing the secretion of aldosterone |
| olmesartan (brand) | benicar |
| olmesartan (class) | angiotensin II receptor blocker (ARB) |
| olmesartan (category) | antihypertensive |
| olmesartan (BMA) | selectively blocks the binding of angiotensin II to the AT1 receptor, preventing vascoconstriction and reducing the secretion of aldosterone |
| enalapril (brand) | vasotec |
| enalapril (class) | angiotensin converting enzyme (ACE) inhibitor |
| enalapril (category) | antihypertensive |
| enalapril (BMA) | inhibits the conversion of angiotensin I to angiotensin II, causing vasodilation and reduction in the release of aldosterone |
| clonidine (brand) | catapres |
| clonidine (class) | alpha 2 adrenergic agonist |
| clonidine (category) | antihypertensive |
| clonidine (BMA) | stimulates alpha 2 adrenergic receptors in the brainstem, reducing sympathetic outflow and decreasing blood pressure |
| diltiazem (brand) | cardizem |
| diltiazem (class) | calcium channel blocker |
| diltiazem (category) | antihypertensive |
| diltiazem (BMA) | inhibits the influx of calcium ions into vascular smooth muscle, leading to vasodilation and reduced heart rate |
| verapamil (brand) | calan, verelan |
| verapamil (class) | calcium channel blocker |
| verapamil (category) | antihypertensive |
| verapamil (BMA) | inhibits the influx of calcium ions into vascular smooth muscle, leading to vasodilation and reduced heart rate |
| metoprolol (brand) | lopressor (tartrate), toprol XL (succinate) |
| metoprolol (class) | beta blocker |
| metoprolol (category) | antihypertensive |
| metoprolol (BMA) | selectively blocks beta 1 adrenergic receptors in the heart and smooth muscle, decreasing heart rate and contractility |
| spironolactone (brand) | aldactone |
| spironolactone (class) | potassium sparing diuretic; aldosterone receptor antagonist |
| spironolactone (category) | antihypertensive |
| spironolactone (BMA) | competes with aldosterone in the distal renal tubules, increasing sodium and water excretion while conserving potassium and hydrogen ions; may block the effect of aldosterone on arteriolar smooth muscle as well |
| chlorthalidone (brand) | hemiclor, thalitone |
| chlorthalidone (class) | thiazide diuretic |
| chlorthalidone (category) | antihypertensive |
| chlorthalidone (BMA) | inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water, as well as potassium and hydrogen ions |
| simvastatin (brand) | zocor |
| simvastatin (class) | HMG- CoA Reductase Inhibitor (statin) |
| simvastatin (category) | antilipemic |
| simvastatin (BMA) | inhibits HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL update from the blood |
| rosuvastatin (brand) | crestor |
| rosuvastatin (class) | HMG-CoA Reductase Inhibitor (Statin) |
| rosuvastatin (category) | antilipemic |
| rosuvastatin (BMA) | inhibits HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL update from the blood |
| atorvastatin (brand) | lipitor |
| atorvastatin (class) | HMG-CoA Reductase Inhibitor (Statin) |
| atorvastatin (category) | antilipemic |
| atorvastatin (BMA) | inhibits HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL update from the blood |
| pravastatin (brand) | pravachol |
| pravastatin (class) | MHG-CoA Reductase inhibitor (statin) |
| pravastatin (BMA) | inhibits HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL update from the blood |
| fenofibrate (brand) | tricor |
| fenofibrate (class) | fibric acid derivative |
| fenofibrate (category) | antilipemic |
| pravastatin (category) | antilipemic |
| fenofibrate (BMA) | activates peroxisome proliferator-activated receptor alpha (PRAR-alpha), leading to increased lipolysis and elimination of triglyceride-rich particles |
| niacin (brand) | niaspan (DSD), niacor |
| niacin (class) | nicotinic acid |
| niacin (category) | antilipemic |
| niacin (BMA) | inhibits lipolysis in adipose tissue, reduces hepatic VLDL synthesis, and increased HDL levels |
| omega-3-acid ethyl esters (brand) | lovaza |
| omega-3-acid ethyl esters (class) | omega-3 fatty acid |
| omega-3-acid ethyl esters (category) | antilipemic |
| omega-3-acid ethyl esters (BMA) | reduces hepatic triglyceride synthesis and increases plasma lipoprotein lipase activity |
| ezetimibe (brand) | zetia |
| ezetimibe (class) | cholesterol absorption inhibitor |
| ezetimibe (category) | antilipemic |
| ezetimibe (BMA) | inhibits the absorption of cholesterol at the brush border of the small intestine |
| evolocumab (brand) | repatha |
| evolocumab (class) | PCSK9 inhibitor |
| evolocumab (category) | antililpemic |
| evolocumab (BMA) | inhibits proprotein convertase subtilisin/kexin type 9 (PCSK 9) which degrades LDL receptors; increases the number of LDL receptors available to clear LDL |
| alirocumab (brand) | praluent |
| alirocumab (class) | PCSK 9 inhibitor |
| alirocumab (category) | antilipemic |
| alirocumab (BMA) | inhibits proprotein convertase subtilisin/kexin type 9 (PCSK 9) which degrades LDL receptors; increases the number of LDL |
| inclisiran (brand) | leqvio |
| inclisiran (class) | small interfering ribonucleic acid (siRNA) agent |
| inclisiran (category) | antililpemic |
| inclisiran (BMA) | inhibits the synthesis of proprotein convertase subtilisin/E47kexin type 9 (PCSK9), increasing the number of LDL receptors available to clear LDL |
| warfarin (brand) | coumadin |
| warfarin (class) | vitamin k antagonist |
| warfarin (category) | anticoagulant |
| warfarin (BMA) | inhibits the synthesis of vitamin k dependent clotting factors II, VII, IX, and X |
| rivaroxaban (brand) | Xarelto |
| rivaroxaban (class) | direct factor Xa inhibitor |
| rivaroxaban (category) | anticoagulant |
| rivaroxaban (BMA) | inhibits factor Xa, preventing the conversion of prothrombin to thrombin |
| apixaban (brand) | eliquis |
| apixaban (class) | direct factor Xa inhibitor |
| apixaban (BMA) | inhibits factor Xa, preventing the conversion of prothrombin to thrombin |
| apixaban (category) | anticoagulant |
| heparin (brand) | hep-lock |
| heparin (class) | anticoagulant |
| heparin (category) | anticoagulant |
| heparin (BMA) | enhances the activity of antithrombin III, inhibiting thrombin and factor Xa |
| enoxaparin (brand) | lovenox |
| enoxaparin (class) | low molecular weight heparin |
| enoxaparin (category) | anticoagulant |
| enoxaparin (BMA) | enhances the activity of antithrombin III, inhibiting thrombin and factor Xa |
| amiodarone (brand) | Nexterone (soln), Pacerone (tab) |
| amiodarone (class) | Class III Antiarrhythmic |
| amiodarone (category) | antiarrhythmic |
| amiodarone (BMA) | inhibits potassium channels responsible for repolarization of the cardiac cell membrane; prolongs the action potential and refractory period of cardiac celia |
| sotalol (brand) | betapace |
| sotalol (class) | class III antiarrhythmic |
| sotalol (category) | antiarrhythmic |
| sotalol (BMA) | nonselectively blocks beta adrenergic receptors and potassium channels to prolong the action potential and refractory period of cardiac cells |
| lidocaine (brand) | xylocaine |
| lidocaine (class) | local anesthetic; class 1b antiarrhythmic |
| lidocaine (category) | antiarrhythmic |
| lidocaine (BMA) | inhibits sodium channels, inhibiting nerve impulse conduction |
| digoxin (brand) | lanoxin |
| digoxin (class) | cardiac glycoside |
| digoxin (category) | antiarrhythmic |
| digoxin (BMA) | affects parasympathetic stimulation, slowing conduction through the AV node and slowing heart rate |
| dofetilide (brand) | tikosyn |
| dofetilide (class) | class III antiarrhythmic |
| dofetilide (category) | antiarrhythmic |
| dofetilide (BMA) | inhibits potassium channels responsible for repolarization of the cardiac cell membrane; prolongs the action potential and refractory period of cardiac cells |
| metformin (brand) | glucophage |
| metformin (class) | biguanide |
| metformin (category) | antidiabetic |
| metformin (BMA) | decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake |
| insulin glargine (brand) | Lantus, Basaglar, Toujeo, and Semglee |
| insulin glargine (class) | long acting insulin |
| insulin glargine (caterogry) | antidiabetic |
| insulin glargine (BMA) | functions as basal glycemic control by regulating glucose metabolism; stimulates glucose uptake in skeletal muscle and fat and inhibits hepatic glucose productions |
| insulin lispro (brand) | Humalog, Admelog, and Lyumjev |
| insulin lispro (class) | rapid acting insulin |
| insulin lispro (category) | antidiabetic |
| insulin lispro (BMA) | functions as bolus glycemic control by regulating glucose metabolism; stimulates glucose uptake in skeletal muscle and fat and inhibts hepatic glucose production |
| insulin aspart (brand) | Novolog, Fiasp, and Merilog |
| insulin aspart (class) | rapid acting insulin |
| insulin aspart (category) | antidiabetic |
| insulin aspart (BMA) | functions as bolus glycemic control by regulating glucose metabolism; stimulates glucose uptake in skeletal muscle and fat and inhibits hepatic glucose production |
| liraglutide (brand) | Victoza, and Saxenda |
| liraglutide (class) | GLP-1 Receptor Agonist |
| liraglutide (category) | antidiabetic |
| liraglutide (BMA) | activates glucagon like peptide 1 (GLP-1) receptor to enhance glucose-dependent insulin secretion, decrease inappropriate glucagon secretion, slow gastric emptying, and decrease food intake |
| semaglutide (brand) | Ozempic, and Wegovy |
| semaglutide (class) | GLP-a Receptor Agonist |
| semaglutide (category) | antidiabetic |
| semaglutide (BMA) | activated GLP-1 receptor to enhance glucose dependent inulin secretion, decrease inappropriate glucagon secretion, slow gastric emptying, and decrease good intake |
| dulaglutide (brand) | Trulicity |
| dulaglutide (class) | GLP-1 Receptor Agonist |
| dulaglutide (catergory) | antidiabetic |
| dulaglutide (BMA) | activate GLP-1 receptor to enhance glucose dependent insulin secretion, decrease inappropriate glucagon secretion, slow gastric emptying, and decrease food intake |
Created by:
agsparks